Traditional Chinese medicine (multi-component)
Assets acting on this target.
- Class
- Oral traditional Chinese medicine formula
By indication
Related mechanisms
Dopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component) (1)HER2 (JSKN003 ADC component) + PD-L1 (envafolimab component) (1)HMG-CoA reductase (atorvastatin component); CBD's cardiometabolic target not established (1)HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component) (1)PCSK9 (laroprovstat component) + HMG-CoA reductase (1)Traditional Uyghur multi-herb honey paste formulation (1)
Traditional Chinese medicine (multi-component) drugs compared
4 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| MLC901NeuroAiD II | Moleac Pte Ltd | botanical | Phase 3 | Phase 3 in Alzheimer's Disease |
| QiShenYiQi | Tasly Pharmaceutical Group | Botanical (TCM) | Phase 3 | Phase 3 in Heart Failure; Phase 2 in Chronic Kidney Disease |
| PM012 | Mediforum Ltd., Co. | botanical | Phase 2/3 | Phase 2/3 in Alzheimer's Disease |
| Jiuweihuaban Pill | Tasly Pharmaceutical Group | small molecule | Phase 2 | Phase 2 in Psoriasis |